Repaglinide and Sitagliptin Constipation Risk
Yes, both repaglinide and sitagliptin can cause constipation, but the risk differs between them: repaglinide causes constipation in 3% of patients (similar to placebo at 2%), while sitagliptin has a notably higher risk with constipation being one of its recognized adverse effects in pooled analyses.
Repaglinide Constipation Profile
According to FDA labeling data, repaglinide causes constipation in 3% of treated patients versus 2% in placebo in pooled 12-24 week controlled trials 1. This represents a minimal increase over baseline rates, making constipation a relatively minor concern with this meglitinide medication.
The most common adverse reactions with repaglinide are actually:
- Upper respiratory infections (16%)
- Headache (11%)
- Hypoglycemia (31% mild-moderate cases)
- Nausea and diarrhea (5% each)
Constipation ranks lower on the adverse event profile and occurs at rates barely distinguishable from placebo 1.
Sitagliptin Constipation Profile
Sitagliptin carries a more significant constipation risk compared to repaglinide. In large pooled safety analyses of 10,246 patients, constipation was specifically identified as having an increased incidence rate in the sitagliptin group compared to non-exposed controls 2. This finding was replicated in an updated analysis of 14,611 patients, where constipation again showed higher rates with sitagliptin treatment 3.
One early analysis noted constipation as one of the main short-term adverse effects of sitagliptin 4. The 2025 ADA guidelines classify DPP-4 inhibitors (including sitagliptin) as having "unknown" risk for gastrointestinal adverse effects, acknowledging that these effects exist but are not fully characterized 5.
Clinical Implications
When constipation is a concern:
- Repaglinide is the safer choice with only 1% absolute risk increase over placebo
- Sitagliptin should be used with awareness of constipation risk and appropriate counseling
- Both medications have other adverse effects that may be more clinically significant (hypoglycemia with repaglinide, upper respiratory infections with sitagliptin)
Important caveats:
- Neither medication approaches the constipation rates seen with other drug classes (e.g., GLP-1 receptor agonists cause constipation with RR 2.41 and 7.39% incidence 6)
- The constipation risk with both agents is generally mild and manageable
- Other factors like concurrent medications, dietary habits, and fluid intake significantly influence constipation risk in diabetic patients
The evidence consistently shows sitagliptin has a more notable association with constipation than repaglinide, though both can cause this adverse effect 1, 3, 2.